Clinical Trial Update: A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating IMO-2125 with 8 mg ipilimumab in metastatic melanoma has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IMO-2125 (IMO-2125)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-08-03